Dicerna Pharmaceuticals (DRNA) PT Raised to $24.00

Dicerna Pharmaceuticals (NASDAQ:DRNA) had its price objective boosted by HC Wainwright from $20.00 to $24.00 in a research report report published on Wednesday morning, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on DRNA. B. Riley lifted their price objective on Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the company a neutral rating in a report on Monday, September 17th. Cowen restated a buy rating on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 5th. BidaskClub upgraded Dicerna Pharmaceuticals from a buy rating to a strong-buy rating in a report on Thursday, August 23rd. Citigroup started coverage on shares of Dicerna Pharmaceuticals in a report on Thursday, September 13th. They issued a buy rating and a $27.00 target price for the company. Finally, Chardan Capital reiterated a hold rating and issued a $14.50 target price on shares of Dicerna Pharmaceuticals in a report on Monday, August 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $19.86.

Shares of DRNA stock traded up $0.23 on Wednesday, hitting $13.39. The stock had a trading volume of 37,658 shares, compared to its average volume of 672,232. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40. The company has a market capitalization of $844.28 million, a P/E ratio of -3.66 and a beta of 2.43. Dicerna Pharmaceuticals has a one year low of $5.24 and a one year high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The firm had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. On average, analysts anticipate that Dicerna Pharmaceuticals will post -1.13 earnings per share for the current fiscal year.

In other news, insider James B. Weissman sold 2,301 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total transaction of $40,267.50. Following the sale, the insider now owns 26,781 shares in the company, valued at $468,667.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Dennis Langer sold 14,531 shares of the business’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total value of $232,496.00. Following the sale, the director now owns 29,064 shares in the company, valued at approximately $465,024. The disclosure for this sale can be found here. Insiders own 19.85% of the company’s stock.

Several hedge funds have recently modified their holdings of DRNA. BlackRock Inc. grew its stake in shares of Dicerna Pharmaceuticals by 839.8% during the second quarter. BlackRock Inc. now owns 2,607,895 shares of the biopharmaceutical company’s stock worth $31,946,000 after acquiring an additional 2,330,402 shares during the last quarter. Emerald Advisers Inc. PA grew its stake in shares of Dicerna Pharmaceuticals by 2,002.5% during the second quarter. Emerald Advisers Inc. PA now owns 603,508 shares of the biopharmaceutical company’s stock worth $7,393,000 after acquiring an additional 574,804 shares during the last quarter. Northern Trust Corp grew its stake in shares of Dicerna Pharmaceuticals by 719.5% during the second quarter. Northern Trust Corp now owns 486,668 shares of the biopharmaceutical company’s stock worth $5,962,000 after acquiring an additional 427,284 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in shares of Dicerna Pharmaceuticals by 72.6% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 909,220 shares of the biopharmaceutical company’s stock worth $13,875,000 after acquiring an additional 382,361 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Dicerna Pharmaceuticals by 509.1% during the first quarter. Millennium Management LLC now owns 407,530 shares of the biopharmaceutical company’s stock worth $3,896,000 after acquiring an additional 340,623 shares during the last quarter. Institutional investors and hedge funds own 74.46% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Story: What is a conference call?

The Fly

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply